col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


31 Results       Page 1

 [1] 
Elsevier: Journal of Virus Eradication
  original article Date Title Authors   All Authors
1 [GO] 2026―May―30 Corticosteroids with or without antiviral therapy in elderly patients hospitalized with COVID-19 during the Omicron era: A multicenter real-world study Shenglin Xu, Zhaohui Huang, Xuejing Zou, Guiping Li, Richeng Mao, Li Liu, et al. (+2)
2 [GO] 2024―Dec―30 FIXATION AND REVERSION OF MUTATIONS IN THE RECEPTOR-BINDING DOMAIN OF SARS-CoV-2 SPIKE PROTEIN : A 2020-2024 ANALYSIS. Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
3 [GO] 2024―Dec―12 Assessing Favipiravir's Impact on SARS-CoV-2 Transmission within Households: Insights from a Multi-center Study (FaviPrev) Taweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, et al. (+5)
4 [GO] 2024―Sep―01 Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: effect on virus-induced COX-2 expression Caterina Tramontozzi, Anna Riccio, Silvia Pauciullo, Simone La Frazia, Antonio Rossi, M. Gabriella Santoro
5 [GO] 2024―Jun―12 Vaccination against COVID-19 among Healthcare Workers as a Cocoon Strategy for People Living with HIV Agata Skrzat-Klapaczyńska, Justyna Kowalska, Filip Fijołek, Marcin Paciorek, Carlo Bieńkowski, Dominika Krogulec, Andrzej Horban
6 [GO] 2023―May―26 Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies Nimer Mehyar
7 [GO] 2023―Mar―10 The poliovirus reemergence: Did concentrated efforts against COVID-19 open the door? Nour Shaheen, Abdelrahman Mohamed, Abdelraouf Ramadan, Abdulqadir J. Nashwan
8 [GO] 2022―Dec―20 PP 1.37 - 00186 Investigating Short-Term Effects of COVID-19 mRNA Vaccination on Plasma Viremia and Intact HIV Reservoir Size in Individuals Receiving Antiretroviral Therapy (ART) M.C. Duncan, F.H. Omondi, N.N. Kinloch, H.R. Lapointe, S. Speckmaier, N. Moran-Garcia, et al. (+6)
9 [GO] 2022―Dec―20 PP 7.4 - 00016 Acquisition of SARS-CoV-2 infection during an HIV cure study with an ATI period I. Mcgowan, L. Bailon, S. Devi, C. Brander, J.R. Arribas
10 [GO] 2022―Dec―20 PP 4.19 - 00021 Impact of SARS-COV-2-Mediated CD4 T Cell Activation HIV DNA Persistence In Vivo T.-M. Deveau, M. Peluso, A. Buck, N. Kumar, T. Henrich
11 [GO] 2022―Dec―13 Evolution of anti-SARS-CoV-2 spike protein titers after two-dose COVID-19 vaccination among people living with HIV Wang-Da Liu, Man Wai Pang, Jann-Tay Wang, Hsin-Yun Sun, Yu-Shan Huang, Kuan-Yin Lin, et al. (+19)
12 [GO] 2022―Dec―09 Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model Yukinori Endo, Brady T. Hickerson, Natalia A. Ilyushina, Nishant Mohan, Hanjing Peng, Kazuyo Takeda, et al. (+2)
13 [GO] 2022―Dec―09 Host-directed therapy with 2-Deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2 Laxmikant Wali, Michael Karbiener, Scharon Chou, Vitalii Kovtunyk, Adam Adonyi, Irene Gösler, et al. (+7)
14 [GO] 2022―Sep―17 Langya virus outbreak in China, 2022: Are we on the verge of welcoming a new pandemic? Shehroze Tabassum, Aroma Naeem, Syeda Tayyaba Rehan, Abdulqadir J. Nashwan
15 [GO] 2021―Sep―16 Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India) Paulo.R.S. Sanches, Ives Charlie-Silva, Helyson.L.B. Braz, Cintia Bittar, Marilia Calmon, Paula Rahal, Eduardo M. Cilli
16 [GO] 2021―Jul―05 Highlights from the virtual conference on retroviruses and opportunistic infections (CROI) 2021: SARS-CoV-2 pathogenesis, new data about antiretroviral treatments, HIV-associated comorbidities, pediatrics and pregnancy Christina K. Psomas, Laura J. Waters, Tristan Barber
17 [GO] 2021―May―19 Induction of Immune Response After SARS-CoV-2 mRNA BNT162b2 Vaccination in Healthcare Workers Salvatore Zaffina, Claudia Alteri, Alessandra Ruggiero, Nicola Cotugno, Maria Rosaria Vinci, Vincenzo Camisa, et al. (+19)
18 [GO] 2021―May―17 Impact of COVID-19 and ICU capacity on vaccination support: Evidence from a two-leg representative survey in the UK Géraldine Blanchard-Rohner, Bruno Caprettini, Dominic Rohner, Hans-Joaquim Voth
19 [GO] 2021―May―08 Prevention and control measures significantly curbed the SARS-CoV-2 and influenza epidemics in China Xiangsha Kong, Feng Liu, Haibo Wang, Ruifeng Yang, Dongbo Chen, Fengmin Lu, et al. (+2)
20 [GO] 2021―Feb―07 Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings. Jillian SY. Lau, Thomas A. Rasmussen, Sharon R. Lewin, Adam Ehm, Cipriano Martinez, Craig Burnett, James H. McMahon
21 [GO] 2021―Feb―06 Commentary Title: COVID-19 Research, Africa, and Global Health Tinkhani Mbichila, Grace Kumwenda, Ntando Yola, Quarraisha Abdool Karim, Tamar Tchelidze, Joseph Lau, et al. (+5)
22 [GO] 2020―Dec―06 HIV cure research in the time of COVID-19 - antiretroviral therapy treatment interruption trials: a discussion paper. S. Fidler, S. Lewin, S. Deeks, O.S. Sogaard, L. Vanderkerckhove, S. Collins, et al. (+4)
23 [GO] 2020―Oct―15 Impact of COVID-19 on people with HIV: A Review Sandeep Prabhu, Selvamuthu Poongulali, Nagalingeswaran Kumarasamy
24 [GO] 2020―Jul―23 SARS coronavirus has antibody-dependent enhancement (ADE) effect through the autologous antibodies against envelope spikes on Fcγ receptor expressing cells Chun-Sheng Yeh, Jyh-Yuan Yang, Wu-Tse Liu, Jason C. Huang, Yi-Ming Arthur Chen, Sheng-Fan Wang
25 [GO] 2020―Jul―23 Human helicase DDX3 as target for broad-spectrum antivirals against pandemic and emerging viruses Annalaura Brai, Roberta Fazi, Cristina Tintori, Josè Estè, Roger Badia, Sandra Franco, et al. (+8)
26 [GO] 2020―Jul―10 Treatment strategies for Middle East respiratory syndrome coronavirus Kayvon Modjarrad
27 [GO] 2020―Jul―09 Climate change, socio-political changes and emerging pandemics Jean-Paul Gonzalez
28 [GO] 2020―Jul―02 Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19 Toby Pepperrell, Victoria Pilkington, Andrew Owen, Junzheng Wang, Andrew M. Hill
29 [GO] 2020―Jul―02 Minimum costs to manufacture new treatments for COVID-19 Andrew Hill, Junzheng Wang, Jacob Levi, Katie Heath, Joseph Fortunak
30 [GO] 2020―Jul―02 A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? Victoria Pilkington, Toby Pepperrell, Andrew Hill
31 [GO] 2020―Jul―02 Summary of the coronavirus disease 2019 (COVID-19) update from the 2020 Conference on Retroviruses and Opportunistic Infections, 8-11 March 2020, Boston, USA Christina K. Psomas, Sabine Kinloch
 [1] 

31 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.003 sec